awmsg logo



regorafenib (Stivarga®)


Reference No. 1018

Publication date:
16/07/2015


Appraisal information

regorafenib (Stivarga®) 40 mg film-coated tablet


Company: Bayer Healthcare Pharmaceuticals
BNF category: Malignant disease and immunosupression
NMG meeting date: 13/05/2015
AWMSG meeting date: 17/06/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1915
Ministerial ratification: 15/07/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Regorafenib (Stivarga®) is recommended for use within NHS Wales for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download